251 related articles for article (PubMed ID: 8475112)
1. Antibody-mediated protection in mice with lethal intracerebral Cryptococcus neoformans infection.
Mukherjee J; Pirofski LA; Scharff MD; Casadevall A
Proc Natl Acad Sci U S A; 1993 Apr; 90(8):3636-40. PubMed ID: 8475112
[TBL] [Abstract][Full Text] [Related]
2. Cryptococcus neoformans infection can elicit protective antibodies in mice.
Mukherjee J; Scharff MD; Casadevall A
Can J Microbiol; 1994 Oct; 40(10):888-92. PubMed ID: 8000967
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice.
Mukherjee S; Lee S; Mukherjee J; Scharff MD; Casadevall A
Infect Immun; 1994 Mar; 62(3):1079-88. PubMed ID: 8112842
[TBL] [Abstract][Full Text] [Related]
4. Effect of antibody to capsular polysaccharide on eosinophilic pneumonia in murine infection with Cryptococcus neoformans.
Feldmesser M; Kress Y; Casadevall A
J Infect Dis; 1998 Jun; 177(6):1639-46. PubMed ID: 9607844
[TBL] [Abstract][Full Text] [Related]
5. Both Th1 and Th2 cytokines affect the ability of monoclonal antibodies to protect mice against Cryptococcus neoformans.
Beenhouwer DO; Shapiro S; Feldmesser M; Casadevall A; Scharff MD
Infect Immun; 2001 Oct; 69(10):6445-55. PubMed ID: 11553589
[TBL] [Abstract][Full Text] [Related]
6. Immunoglobulin G3 blocking antibodies to the fungal pathogen Cryptococcus neoformans.
Nussbaum G; Yuan R; Casadevall A; Scharff MD
J Exp Med; 1996 Apr; 183(4):1905-9. PubMed ID: 8666947
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic efficacy of monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan alone and in combination with amphotericin B.
Mukherjee J; Zuckier LS; Scharff MD; Casadevall A
Antimicrob Agents Chemother; 1994 Mar; 38(3):580-7. PubMed ID: 8203858
[TBL] [Abstract][Full Text] [Related]
8. Cryptococcus neoformans: paradigm for the role of antibody immunity against fungi?
Pirofski LA; Casadevall A
Zentralbl Bakteriol; 1996 Aug; 284(4):475-95. PubMed ID: 8899968
[TBL] [Abstract][Full Text] [Related]
9. Effect of serum IgG1 to Cryptococcus neoformans glucuronoxylomannan on murine pulmonary infection.
Feldmesser M; Casadevall A
J Immunol; 1997 Jan; 158(2):790-9. PubMed ID: 8992996
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo stability of a Cryptococcus neoformans [corrected] glucuronoxylomannan epitope that elicits protective antibodies.
Cleare W; Cherniak R; Casadevall A
Infect Immun; 1999 Jun; 67(6):3096-107. PubMed ID: 10338526
[TBL] [Abstract][Full Text] [Related]
11. T cells cooperate with passive antibody to modify Cryptococcus neoformans infection in mice.
Yuan RR; Casadevall A; Oh J; Scharff MD
Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2483-8. PubMed ID: 9122221
[TBL] [Abstract][Full Text] [Related]
12. Passive immunization against Cryptococcus neoformans with an isotype-switch family of monoclonal antibodies reactive with cryptococcal polysaccharide.
Sanford JE; Lupan DM; Schlageter AM; Kozel TR
Infect Immun; 1990 Jun; 58(6):1919-23. PubMed ID: 2341184
[TBL] [Abstract][Full Text] [Related]
13. Variable efficacy of passive antibody administration against diverse Cryptococcus neoformans strains.
Mukherjee J; Scharff MD; Casadevall A
Infect Immun; 1995 Sep; 63(9):3353-9. PubMed ID: 7642262
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and biodistribution of a monoclonal antibody to Cryptococcus neoformans capsular polysaccharide antigen in a rat model of cryptococcal meningitis: implications for passive immunotherapy.
Goldman DL; Casadevall A; Zuckier LS
J Med Vet Mycol; 1997; 35(4):271-8. PubMed ID: 9292424
[TBL] [Abstract][Full Text] [Related]
15. Human immunoglobulin G2 (IgG2) and IgG4, but not IgG1 or IgG3, protect mice against Cryptococcus neoformans infection.
Beenhouwer DO; Yoo EM; Lai CW; Rocha MA; Morrison SL
Infect Immun; 2007 Mar; 75(3):1424-35. PubMed ID: 17220317
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of immune sera from human immunoglobulin transgenic mice immunized with a peptide mimotope of Cryptococcus neoformans glucuronoxylomannan.
Maitta RW; Datta K; Pirofski LA
Vaccine; 2004 Sep; 22(29-30):4062-8. PubMed ID: 15364457
[TBL] [Abstract][Full Text] [Related]
17. Immunoglobulin M efficacy against Cryptococcus neoformans: mechanism, dose dependence, and prozone-like effects in passive protection experiments.
Taborda CP; Casadevall A
J Immunol; 2001 Feb; 166(3):2100-7. PubMed ID: 11160261
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole efficacy.
Mukherjee J; Feldmesser M; Scharff MD; Casadevall A
Antimicrob Agents Chemother; 1995 Jul; 39(7):1398-405. PubMed ID: 7492075
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibody to fungal glucosylceramide protects mice against lethal Cryptococcus neoformans infection.
Rodrigues ML; Shi L; Barreto-Bergter E; Nimrichter L; Farias SE; Rodrigues EG; Travassos LR; Nosanchuk JD
Clin Vaccine Immunol; 2007 Oct; 14(10):1372-6. PubMed ID: 17715331
[TBL] [Abstract][Full Text] [Related]
20. The mouse antibody response to infection with Cryptococcus neoformans: VH and VL usage in polysaccharide binding antibodies.
Casadevall A; Scharff MD
J Exp Med; 1991 Jul; 174(1):151-60. PubMed ID: 1676047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
